Recce Pharmaceuticals Ltd

Research Recce Pharmaceuticals Ltd (RCE) on Bullrun: market cap AUD 133.02M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRCE
• ExchangeAU
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyAUD
• Market capAUD 133.02M
• Financial periodFY2025
• Net income-AUD 21.43M
• Free cash flow-AUD 20.47M

Valuation Snapshot

latest market cap is AUD 133.02M.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis;

Frequently asked questions

What is Recce Pharmaceuticals Ltd's market cap?

Recce Pharmaceuticals Ltd's market capitalization is AUD 133.02M.

What does Recce Pharmaceuticals Ltd do?

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections.